Attached files

file filename
EX-32.1 - EXHIBIT 32.1 - Anika Therapeutics, Inc.exh_321.htm
EX-31.2 - EXHIBIT 31.2 - Anika Therapeutics, Inc.exh_312.htm
EX-31.1 - EXHIBIT 31.1 - Anika Therapeutics, Inc.exh_311.htm
EX-23.2 - EXHIBIT 23.2 - Anika Therapeutics, Inc.exh_232.htm
EX-21.1 - EXHIBIT 21.1 - Anika Therapeutics, Inc.exh_211.htm
10-K - FORM 10-K - Anika Therapeutics, Inc.f10k_022618p.htm

EXHIBIT 23.1

 

CONSENT OF INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM

 

We consent to the incorporation by reference in the Registration Statements on Form S-8 (Nos. 333-06275, 333-66831, 333-79047, 333-58264, 333-110326, 333-160102, 333-176103, 333-190597 and 333-219190) of Anika Therapeutics, Inc. of our reports dated February 26, 2018 relating to the financial statements of Anika Therapeutics, Inc. (the “Company”) and the effectiveness of the Company’s internal control over financial reporting, appearing in this Annual Report on Form 10-K of Anika Therapeutics, Inc. for the year ended December 31, 2017. 

 

/s/ Deloitte & Touche LLP

 

Boston, Massachusetts

February 26, 2018